Cullinan Therapeutics, Inc. (NASDAQ: CGEM)

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, operates in the biotechnology industry. Its primary business activities involve the development of modality-agnostic targeted oncology therapies. The company seeks to create new standards of care for patients by identifying high-impact cancer targets and selecting the optimal therapeutic modality for those targets. Cullinan Therapeutics operates in the United States and has a global presence through its clinical trials and partnerships.

Cullinan Therapeutics generates revenue primarily through the development and clinical trials of its targeted oncology therapies. The company's primary products and services include CLN-619, a MICA/B-targeted humanized immunoglobulin G1 (IgG1) monoclonal antibody, and CLN-978, a CD19xCD3 T cell engager with extended serum half-life. These products are being evaluated in clinical trials for patients with advanced solid tumors and relapsed/refractory B cell non-Hodgkin lymphoma (B-NHL), respectively. Additionally, Cullinan Therapeutics is developing zipalertinib, an orally-available small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor, in collaboration with an affiliate of Taiho Pharmaceutical Co., Ltd. Zipalertinib is being evaluated in a pivotal Phase 2b clinical trial for patients with EGFR exon 20 (EGFRex20) non-small-cell lung cancer (NSCLC) who progressed after prior systemic therapy.

Within the industry, Cullinan Therapeutics competes with other biotechnology and pharmaceutical companies, including Bristol-Myers Squibb Company, CanCure LLC, D2M Biotherapeutics, Inc., Genentech Inc., Novartis International AG, and Xencor, Inc. The company's competitive advantages include its focus on modality-agnostic targeted oncology therapies, its rigorous and differentiated approach to drug development, and its ability to leverage its internal expertise and external partnerships to develop novel product candidates.

Cullinan Therapeutics' customers include patients with advanced solid tumors, B-NHL, and other indications, as well as healthcare providers and payers. The company's products are designed to address significant unmet needs in these indications, and the company believes that its products have the potential to become new standards of care for patients.

The brand names and/or trade names of Cullinan Therapeutics' products and services include CLN-619, CLN-978, and zipalertinib. The company's intellectual property is critical to its business, and it strives to protect it by obtaining, maintaining, defending, and enforcing patents and other intellectual property in the U.S. and internationally. Cullinan Therapeutics does not own or operate any good manufacturing practice (GMP) manufacturing facilities and relies on third-party manufacturers for the production of its clinical trial materials. The company's partnerships and collaborations, including those with Adimab and Icahn School of Medicine at Mount Sinai, further strengthen its position in the industry.